The British Academy Conference on “Resolving Global Vaccine Inequity: Innovation, Capabilities and Governance” co-organized by SOAS and AIRNET

On April 11-12, 2024, SOAS University of London and the Academic-Industry Research Network, co-hosted the British Academy Conference on “Resolving Global Vaccine Inequity: Innovation, Capabilities and Governance” to gather biomedical and social scientists, public health practitioners, and policy makers to…

Experts: Negotiating Big Pharma’s Prices Won’t Stifle Innovation—They Don’t Use the Money to Innovate!

Lynn Parramore explains how physician-scientist Fred Ledley and economist William Lazonick debunked the arguments of “industry lobbyists vehemently oppose Medicare drug price negotiations”. Click HERE to read the article at

Business Insider quotes and cites AIRnet research on Boeing’s stock buybacks.

Business Insider quotes and cites President of AIRnet Bill Lazonick’s INET-funded research on Boeing’s stock buybacks. The article is also cross-posted in MSN, Yahoo Finance, Business News, AOL, News Break, Star News, and Web Today.

Creating value or extracting it? An existential question.

In her blog “Thought Sparks“, Rita McGrath quotes and cites Lazonick’s book, Investing in Innovation: Confronting Predatory Value Extraction in the U.S. Corporation, and discuses “a board and governance level issue that doesn’t get nearly enough attention is whether firms…

Investing in Innovation

Confronting Predatory Value Extraction in the U.S. Corporation by William Lazonick Business corporations interact with household units and government agencies to make investments in productive capabilities required to generate innovative goods and services. When they work harmoniously, these three types…


With working Americans’ survival at stake, the US is bailing out the richest

“Amid a humanitarian crisis compounded by mass layoffs and collapsing economic activity, the last course our legislators should be following is the one they appear to be on right now: bailing out shareholders and executives who, while enriching themselves, spent…

US Pharma’s Financialized Business Model

By William Lazonick, Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç and Öner Tulum ◊ Price gouging in the US pharmaceutical drug industry goes back more than three decades. In 1985 US Representative Henry Waxman, chair of the House Subcommittee on Health and the Environment, accused the pharmaceutical industry of “gouging the American public” with “outrageous” price increases, driven by “greed on a massive scale.” Even in the wake of the many Congressional inquiries that have taken place since the 1980s, including one inspired by the extortionate prices that Gilead Sciences has placed on its Hepatitis-C drugs Sovaldi since 2013 and Harvoni since 2014, the US government has not seen fit to regulate drug prices. UK Prescription Price Regulation Scheme data for 1996 through 2010 show that, while drug prices in other advanced nations were close to the UK’s regulated prices, those in the United States were between 74 percent and 181 percent higher.